MK-1026-010
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab in Second-line + Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma .
Recruiting
Trial purpose
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).
View full trial information on Clinicaltrials.govNATIONAL TRIAL REFERENCE NUMBER
NCT05947851
When you talk with your doctor or clinical trial team member, please have the national trial reference number available.
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
CLL, Leukemia, Chronic Lymphocytic, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic, SLL, Small-Cell Lymphoma
Age Range
18+
Sex
Male/Female
About the trial
Current trial Phase
Phase 3
Tests the medicine or vaccine in approximately 1,000 to 5,000 participants. For medicines, participants have the disease or condition the medicine is designed to treat. In vaccine trials, the participants may be healthy or have diseases or conditions. Phase 3 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial start and end dates
- Trial start date 08-08-2023
- Estimated primary completion date 06-01-2032
- Estimated trial completion date 07-01-2035
Trial Locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.